Recombinant Human Endothelial-MonocyteAActivating Polypeptide II (rHuEMAP-II)
EMAP-II is a tumor derived cytokine that exerts a wide range of activities on endothelial cells, monocytes and neutrophils. EMAP-II inhibits endothelial cell proliferation, vasculogenesis, neovessel formation, and can induce apoptosis. It is also chemotactic towards neutrophils and monocytes and induces myeloperoxidase activity from neutrophils. Of clinical importance, EMAP-II inhibits angiogenesis of vascular beds and suppresses the growth of primary and secondary tumors without affecting normal tissues. Mature EMAP-II is an 18.3 kDa protein, which is synthesized as the C-terminal portion of a biologically inactive precursor protein containing a propeptide of 146 amino acid residues.
Product Specifications
CAS Number
9000-83-3
Endotoxin
Less than 1EU/mg of rHuEMAP-II as determined by LAL method.
Purity
>98% by SDS-PAGE and HPLC analyses.
Bioactivity
Determined by the apoptotic effect on MCF-7 cells using a concentration of 20-40 ng/ml, corresponding to a Specific Activity of > 2.5 x 104 IU/mg.
Reconstitution
Molecular Weight
Approximately 18.3 KDa, a single non-glycosylated polypeptide chain containing 166 amino acids.
Storage Conditions
Appearance
Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation
Lyophilized from a 0.2mm filtered concentrated solution in 20mM PB, pH 7.4, 130mM NaCl.
Host or Source
Escherichia coli.
Recommended Usage
This material is offered by USA Bioworld biotech for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE. Made in China
AA Sequence
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Mouse IgG3 (Fcγ Fragment specific), AlpHcAbs® Goat antibody (HRP)
